Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now full pipeline small index

Lyme Disease: full-pipeline trial registry

5 of 10 indexed Lyme Disease trials are currently recruiting.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Lyme Disease: 10 US clinical trials tracked, 5 recruiting.

Lyme Disease is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 4 of these trials.

Enrollment posture brief

Registry condition lyme-disease

OPEN 5 | RECR 50% | LATE 3 | EARLY 2 | RANK #1724 | SPON 4

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Lyme Disease (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Lyme Disease

Lyme Disease lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lyme Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lyme Disease is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Lyme Disease research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 4 of 10 trials (40%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lyme Disease enrolment sits around 500 participants.

    Median target enrolment is 500 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.

  4. Lyme Disease splits between interventional and observational designs.

    5 interventional and 5 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 33

Open and recent trials

10 total, page 1 of 1

RECRUITING 700 participants

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001539

RECRUITING 500 participants

Evaluation, Treatment, and Follow-up of Patients With Lyme Disease

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00028080

RECRUITING Phase 1 60 participants

Human Immune Response to Ixodes Scapularis Tick Bites

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05036707

RECRUITING 40 participants

Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure

Children's National Research Institute

NCT06026969

RECRUITING 30 participants

Navigating Pregnancy and Parenthood With Lyme Disease

Children's National Research Institute

NCT06397794

ACTIVE NOT RECRUITING Phase 3 12,547 participants

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Pfizer

NCT05477524

COMPLETED Phase 3 20,000 participants

Lyme Disease Prevention Program

Brigham and Women's Hospital

NCT00000432

COMPLETED 893 participants

ImmuneSense Lyme Study

Adaptive Biotechnologies

NCT04422314

COMPLETED Phase 3 55 participants

Study and Treatment of Post Lyme Disease (STOP-LD)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00000937

COMPLETED Phase 1 44 participants

First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

MassBiologics

NCT04863287

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 3 3

Named interventions

Most-linked intervention names on Lyme Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

0.9% Sodium Chloride (NaCl) Other
1 trials
2217LS Biological
1 trials
T-Detect Lyme Diagnostic test
1 trials
Education about disease prevention Behavioral
1 trials
Quantitative surveys and qualitative interview Other
1 trials
Antibiotics Drug
1 trials
VLA15 Biological
1 trials
Neurodevelopmental assessments and follow-up Other
1 trials

US sites by state

Facility locations filed on Lyme Disease trials. A trial with sites in several states counts in each.

Maryland 5 trials
Massachusetts 3 trials
New York 2 trials
Maine 2 trials
Connecticut 2 trials
Pennsylvania 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lyme Disease page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lyme Disease condition card totals 10 registered trials; most-linked intervention 0.9% Sodium Chloride (NaCl); top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.